UK Researchers Developing Duplex qPCR Assay to Monitor BCR-ABL1-Linked Blood Cancers
March 03, 2011
UK Researchers Developing Duplex qPCR Assay to Monitor BCR-ABL1-Linked Blood Cancers
The group from Imperial College London's Hammersmith Hospital has developed a duplex qPCR assay that measures both BCR-ABL1 target and endogenous control transcripts in the same reaction with no loss of sensitivity compared to a previously used simplex test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Life Tech Acquisition Would Make Thermo Fisher a Leader in PCR Research Tools, Forensic Analysis
April 18, 2013 / PCR Insider - Insight Genetics Wins $1.5M Grant to Begin Clinical Testing for ALK Mutation CDx on Qiagen Platform
October 11, 2012 / PCR Insider - Multicenter Study Further Debunks Link Between Chronic Fatigue Syndrome, Murine Viruses
September 20, 2012 / PCR Insider - Quidel Expands Market for Flu Assay with Second Platform Approval
March 22, 2012 / PCR Insider - PCR Licensing Deal Validates Roche IP; Bolsters Life Tech's Ongoing Push into IVD Market
February 23, 2012 / PCR Insider